Text Size

Effect of Aging on Haemostasis Parameters

This study has been completed.
Sponsor:
Information provided by:
Hopital Lariboisière
ClinicalTrials.gov Identifier:
NCT00299624
First received: March 6, 2006
Last updated: September 13, 2010
Last verified: September 2010
History of Changes
  Purpose

Aging is an independent risk factor, without any clear explanation. The primary aim of the study is to depict the effect of aging on the coagulation fibrinolysis parameters and microparticles.


Condition
Aging

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identifying Morphological and Biological Biomarkers of the Venous Thromboembolic Risk Risk Related to Aging

Further study details as provided by Hopital Lariboisière:

Estimated Enrollment: 100
Study Start Date: October 2005
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Patients older than 40, without any acute disease and not receiving any antiaggregant and anticoagulant therapy will be included in the study. Blood tests will be performed for coagulation, fibrinolysis and microparticles measurement.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Stable patients without overt acute clinical event, not receiving antiplatelet or anticoagulant treatment

Criteria

Inclusion Criteria:

  • age <40 2 groups : 1 : no history of VTE 2 : history of VTE

Exclusion Criteria:

  • antiaggregant or anticoagulant therapy at curative dose
  • arterial or thrombotic event in the last month
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00299624

Locations
France
Hopital Lariboisière
Paris, France, 75010
Hopital Lariboisiere
Paris, France, 75010
Sponsors and Collaborators
Hopital Lariboisière
Investigators
Principal Investigator: isabelle mahé, MD PhD MCU-PH
  More Information

No publications provided

Responsible Party: Pr Isabelle MAHE, Hopital Lariboisière
ClinicalTrials.gov Identifier: NCT00299624     History of Changes
Other Study ID Numbers: TAPH
Study First Received: March 6, 2006
Last Updated: September 13, 2010
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Hopital Lariboisière:
venous thromboembolism risk,
elderly,
hypercoagulability
fibrinolysis
microparticles

ClinicalTrials.gov processed this record on June 17, 2013